Collectively, these findings suggest that targeting DAT residues Tyr88 and His547 may have potential therapeutic benefits on Tat-induced dysregulation of dopaminergic system seen in patients with HAND. Here, SLC6A3 is linked to HIV-associated neurocognitive disorder.